<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="843">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150184</url>
  </required_header>
  <id_info>
    <org_study_id>NH10009</org_study_id>
    <nct_id>NCT05150184</nct_id>
  </id_info>
  <brief_title>Isolation and Characterization of Multiple Microbial Species From Diverse Healthy Adults</brief_title>
  <acronym>IsoMic</acronym>
  <official_title>Isolation and Characterization of Fecal/Oral/Skin/Nasal/Throat Microbial Species From a Diverse Cohort of Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reprocell Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Serologix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolation and characterization of fecal/oral/skin/nasal/throat microbial species from a&#xD;
      diverse cohort of healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims at isolation and characterizing microbial species from the diverse cohort for&#xD;
      future development as next generation probiotics and includes the characterization of the&#xD;
      human fecal/oral/skin/nasal and throat microbiome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of microbiomes from various body sites</measure>
    <time_frame>within 2 weeks of collection</time_frame>
    <description>Analysis of microbiomes from various body sites</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Human Microbiome</condition>
  <arm_group>
    <arm_group_label>Healthy adults, various ethnicities</arm_group_label>
    <description>Non-interventional</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional</intervention_name>
    <description>observational</description>
    <arm_group_label>Healthy adults, various ethnicities</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy donors of various ethnicities, within normal BMI range.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary, written, informed consent to participate in the study&#xD;
&#xD;
          2. Agreement to comply with the protocol and study restrictions&#xD;
&#xD;
          3. Healthy females and males of age 18 to 50 years (inclusive)&#xD;
&#xD;
          4. Participants recognize themselves as white or American Indian or Alaska Native or&#xD;
             Asian or Black / African American or Native Hawaiian or Other Pacific Islander or&#xD;
             Hispanic and Latinos or Multiracial. Participant numbers are limited to a maximum of&#xD;
             10 (males and females) from each group.&#xD;
&#xD;
          5. Participants consume &gt; 4 portions of fruits and vegetables per day and who agree to&#xD;
             maintain their usual dietary habits, their usual exercise habits, hygienic habits and&#xD;
             their lifestyle in general throughout the trial period&#xD;
&#xD;
          6. Females of child-bearing potential who agree to use medically approved methods of&#xD;
             birth control&#xD;
&#xD;
          7. Ability of the participant (in the investigator's opinion) to comprehend the full&#xD;
             nature and purpose of the study&#xD;
&#xD;
          8. BMI between 18.5-25.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in a clinical trial with an investigational product or drug within 60&#xD;
             days prior to screening.&#xD;
&#xD;
          2. Likeliness to be noncompliant with the protocol, or to be unsuitable to the study as&#xD;
             judged by the study staff for any reason.&#xD;
&#xD;
          3. Planned major changes in life style (i.e. diet, dieting, exercise level, travelling).&#xD;
&#xD;
          4. History of diagnosed eating disorder (anorexia, bulimia).&#xD;
&#xD;
          5. Consumption of fast food &gt; 3 times/week. Where fast food is referred to high&#xD;
             carbohydrate and fat rich diet.&#xD;
&#xD;
          6. History of drug (&gt; 2 times per week) during last 2 years or alcohol abuse (&gt; 08&#xD;
             portions per week for females and 15 portions/week for males, or &gt;3 portions/day)&#xD;
             during the last 3 months.&#xD;
&#xD;
          7. Pregnant or breastfeeding women; women planning to become pregnant during the study.&#xD;
&#xD;
          8. Clinically significant underlying systemic illness that may preclude the participant's&#xD;
             ability to complete the trial or that may affect the study outcomes (e.g. bowel&#xD;
             cancer, prostate cancer, terminal illness, coronary heart disease/cardiovascular&#xD;
             disease or artificial heart valve, HIV, STD, AIDS, hepatitis and autoimmune diseases&#xD;
             e.g. MS-disease, thyroid diseases)&#xD;
&#xD;
          9. Use of prescription anti-obesity drugs, temporary or irregular medication for&#xD;
             diabetes, dyslipidemia or hypertension, non-steroidal anti-inflammatory drugs,&#xD;
             corticosteroids, or equivalent immunomodulatory drugs, immunosuppression or ongoing&#xD;
             therapy causing immunosuppression and ongoing or recent (last 3 months) antibiotic&#xD;
             treatment.&#xD;
&#xD;
         10. Diagnosed or suspected organic gastrointestinal disease (e.g. colitis, Crohn's&#xD;
             disease, celiac disease, recurrent diverticulitis) or non-organic disease (e.g. IBS),&#xD;
             or functional constipation, during the last year.&#xD;
&#xD;
         11. Colonoscopy within 3 months before screening&#xD;
&#xD;
         12. Colon cleansing within 3 months before screening.&#xD;
&#xD;
         13. Gastrointestinal infection within 6 months before screening&#xD;
&#xD;
         14. Active or recent (last 3 months) participation in a weight loss program including&#xD;
             weight change (increase or loss) of 3 kg during the past three months. History of&#xD;
             bariatric surgery.&#xD;
&#xD;
         15. History of gingivitis, periodontitis, or any oral disease during last 6 months.&#xD;
&#xD;
         16. History of smoking or tobacco use in any form and/or electronic cigarette during the&#xD;
             last 6 months.&#xD;
&#xD;
         17. History of skin diseases (e.g. atopic dermatitis (Eczema), hives, dermatitis,&#xD;
             psoriasis, or rashes) during the last 6 months.&#xD;
&#xD;
         18. History of SARS CoV-2 infection.&#xD;
&#xD;
         19. Participants under administrative or legal supervision.&#xD;
&#xD;
         20. Other reasons that, in the opinion of the Investigator, make the participant&#xD;
             unsuitable for enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Teresa A Lehman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reprocell</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa A Lehman, PhD</last_name>
    <phone>2407841234</phone>
    <email>terri@reprocell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramakrishna V Modali, MS</last_name>
    <phone>2407841235</phone>
    <email>rama@reprocell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reprocell</name>
      <address>
        <city>Beltsville</city>
        <state>Maryland</state>
        <zip>20705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri A Lehman, PhD</last_name>
      <phone>240-784-1234</phone>
    </contact>
    <contact_backup>
      <last_name>Ramakrishna V Modali, MS</last_name>
      <phone>2407841235</phone>
      <email>terri@reprocell.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided as of now</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

